Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Evolocumab Added to Moderate-Intensity Statin Therapy on LDL-C Lowering and Cardiovascular Adverse Events in Patients With Acute Coronary Syndrome

NCT04100434 is registered in ClinicalTrials.gov with Tianjin Chest Hospital as lead sponsor.

NCT NCT04100434
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04100434 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Evolocumab Added to Moderate-Intensity Statin Therapy on LDL-C Lowering and Cardiovascular Adverse Events in Patients With Acute Coronary Syndrome
Lead sponsor
Tianjin Chest Hospital
Phase
Phase 4
Overall status
Unknown status
Start date
January 1, 2021
Completion date
June 1, 2023
Enrollment
500 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute coronary syndrome, proprotein convertase subtilisin/kexin type 9 inhibitor